2 withdrawn, 1 completed, 1 terminated. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Withdrawn 2, Completed 1, Terminated 1 |
Follow Pituitary Tumor: new trials by email Literature Review of Pituitary Tumor trials Research Report on Pituitary Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery Tranexamic acid, Placebo - Pituitary Tumor, Blood Loss | Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2022-03-01 | 2022-04-05 | |
| Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors Ipilimumab, Nivolumab - Pituitary, Pituitary Tumor | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 10 | 2019-07-31 | 2026-06-02 |
| Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors Pasireotide LAR - Pituitary Tumor, ACTH-producing Pituitary Tumour | Phase 2 | Terminated | Columbia University | 4 | 2017-07-10 | 2021-04-27 |
| Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy antineoplaston A10, antineoplaston AS2-1, alternative product therapy - Merkel Cell Carcinoma, Islet Cell Carcinoma | Phase 2 | Withdrawn | Burzynski Research Institute | 2013-07-10 |
Pituitary Neoplasms (4) · Carcinoma, Islet Cell (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Neuroendocrine (1) · Growth Hormone-Secreting Pituitary Adenoma (1) · Hemorrhage (1) · Pituitary Diseases (1) · Somatostatinoma (1)
Brain Diseases (4) · Brain Neoplasms (4) · Central Nervous System Diseases (4) · Central Nervous System Neoplasms (4) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Hypothalamic Diseases (4) · Hypothalamic Neoplasms (4) · Neoplasms (4) · Neoplasms by Site (4) · Nervous System Diseases (4) · Nervous System Neoplasms (4) · Supratentorial Neoplasms (4) · Pituitary Diseases (3) · Adenocarcinoma (1)
Biological Therapy (1) · Complementary Therapies (1) · Ipilimumab (1) · Nivolumab (1) · Tranexamic Acid (1) · antineoplaston A10 (1) · antineoplaston AS 2-1 (1)
Burzynski Research Institute (1) · Columbia University (1) · Memorial Sloan Kettering Cancer Center (1) · University of North Carolina, Chapel Hill (1)
United States (3)
Andrew Lin, MD (1) · Brent Senior, MD (1) · Pamela Freda, MD (1) · Stanislaw R. Burzynski, MD, PhD (1)